Research Chemist National Institute of Standards and Technology (NIST) Rockville, Maryland
Cell and gene therapies promise to become revolutionary curative treatments, yet realization of this potential requires advances in biomolecular understanding to be on par with quality standards of today’s state-of-the art treatments (e.g. monoclonal antibodies). Characterization of mAbs has evolved during the past 30 years to include a toolbox of measurements to elucidate identity, quality, and stability. Molecular complexity is magnified significantly with cell and gene therapies, as is the need to pursue adaptation, targeted innovation, translation, and implementation of high resolution analytical measurement approaches to further the understanding and development of these novel modalities. This talk will describe translation of principles of the multi-attribute mass spectrometry method (MAM) toward 1) identification and control of viral vector quality attributes and 2) adaptation of these principles toward comprehensive proteome characterization of CAR-T cells.
Upon completion, participans will be able to explore opportunities with their own organization where the principles of MAM, including attribute control and new peak detection, may be utilized.
Upon completion, participans will be able to Implement a roadmap that bridges learnings from MAM of mAbs to viral vector mediated therapies.
Upon completion, participans will be able to understand and execute the potential benefits of merging of discovery proteomics with MAM principles to translate mass spectrometry into a disruptive technology for cell therapy including CAR-T.